Key facts
- Thorough Future’s last known valuation is $18.3M (May 2020).
- It has raised $123.9M; the latest was Later Stage VC in Mar 2025.
- Notable investors include Korea Investment Partners, Qiming Venture Partners, Puhua Capital, BridgeOne Capital China, Hongdao Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Thorough Future
- ·The full record, as it builds
Funding rounds
No funding rounds for Thorough Future are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Thorough Future
Developer of an AI-driven pathology imaging platform aims to enhance diagnostic accuracy and accelerate digital transformation in pathology. The company's platform features intelligent detection, diagnostic, and predictive technologies powered by big data and artificial intelligence, helping hospitals and laboratories achieve efficient analysis, improve patient outcomes, and drive the adoption of smart pathology systems across China and the Asia-Pacific region.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2017
- Employees
- 30
- Website
- thorough.ai/
- Ownership
- Privately Held (backing)
Thorough Future doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Thorough Future shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Thorough Future in its N-PORT filings yet. We sweep new filings monthly.